Screener
Pacira BioSciences, Inc. PCRX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028871
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Effect of exchange rate changes on cash and cash equivalents | 38 | — |
| Net (decrease) increase in cash and cash equivalents | (14,239) | 6,836 |
| Cash and cash equivalents, beginning of period | 158,545 | 276,774 |
| Cash and cash equivalents, end of period | $144,306 | $283,610 |
| Supplemental cash flow information: | ||
| Cash paid for interest | $1,595 | $2,715 |
| Net cash paid for income taxes | $50 | $286 |
| Non-cash investing and financing activities: |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Pacira BioSciences, Inc.'s cash & equivalents?
- Pacira BioSciences, Inc. (PCRX) reported cash & equivalents of $144.31M in Q1 2026.
- How has Pacira BioSciences, Inc.'s cash & equivalents changed year-over-year?
- Pacira BioSciences, Inc.'s cash & equivalents decreased by 49.1% year-over-year, from $283.61M to $144.31M.
- What is the long-term trend for Pacira BioSciences, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s cash & equivalents has grown at a 9.7% compound annual growth rate (CAGR), from $99.96M to $158.55M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Pacira BioSciences, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude